Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States.
$67.30-0.40%
报价 2026-11-06
市值
$29.97B
EV
$27.87B
PE (TTM)
25.6x
预期 PE (FY2026)
12.6x
52 周区间距高点 -0.4%
$38.09$67.57
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-07不在筛选范围：industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| RPRXRoyalty Pharma plc | $29.97B | -0.4% | +14.8% | 100% | 25.6x | 17.1x | 12.1x | |
| GMABGenmab A/S | $32.98B | +1.7% | – | 39.9% | 45.6x | 28.5x | 41.3x | |
| ROIVRoivant Sciences Ltd. | $28.08B | +6.2% | – | 81.2% | – | – | – | |
| INCYIncyte Corporation | $24.39B | +1.4% | +12.9% | 91.8% | 13.9x | 8.5x | 17.9x | |
| UTHRUnited Therapeutics Corporation | $24.11B | -0.7% | +1.9% | 86.1% | 17.9x | 12.8x | 21.0x | |
| THCTenet Healthcare Corporation | $22.55B | -1.1% | +4.8% | 62.5% | 8.2x | 5.6x | 6.8x | Cheap |
| EXELExelixis, Inc. | $17.49B | +1.3% | +11.8% | 96.4% | 14.4x | 11.5x | 20.6x | |
| SNNSmith & Nephew plc | $13.54B | -2.7% | – | 68% | 22.0x | 10.3x | – | |
| SMMTSummit Therapeutics Inc. | $13.03B | +15.1% | -82.9% | 0% | – | – | – | |
| 同行中位数 | – | – | +4.8% | 74.6% | 16.1x | 10.9x | 20.6x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。